This is a single-arm, open-label, multicenter trial. Patients given SGN-LIV1A in Part A will be monitored for frequency of dose-limiting toxicities to determine if dosing should be de-escalated before opening the expansion in Part B. In addition to safety measures, objective response rate, progression-free survival, overall survival, and other efficacy outcomes will be assessed.